Patients in bind as brain cancer drug price rises to $1,000 per pill

Patients in bind as brain cancer drug price rises to $1,000 per pill

The maker of the expensive brain cancer drug Gleostine has removed it from the Medicare drug rebate program, a move that could have dire consequences for some patients.

The drug from NextSource Biotechnology is used to treat glioblastoma and other brain cancers and can cost as much as $1,000 a capsule. The Gleostine patent has expired, but there is no generic version, CBS News reported. The company's decision—which means there is one less option in a limited number of approved chemotherapies—was criticized by brain tumor experts and patient advocates.

"The decision by the company to withdraw from public health insurance programs weakens the safety net for vulnerable patients who already have few treatment options," David Arons, CEO of the National Brain Tumor Society, told CBS Moneywatch. "We urge NextSource to rejoin these programs and help reduce barriers for patients who require access to this therapy as well as for researchers and clinical trial participants participating in critical, ongoing studies."

"Lomustine [Gleostine] is one of only three FDA-approved chemotherapies for patients with glioblastoma and the one that most patients receive when their tumor progresses on first-line temozolomide chemotherapy. The for patients with glioblastoma is 65, meaning the decision to no longer participate in the Medicare program affects half of the glioblastoma population," Patrick Wen, M.D., director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute in Boston, told CBS Moneywatch. "The only other treatment is avastin. Lomustine is also the standard-of-care treatment used in the control arm of most recurrent glioblastoma , and not having easy access to this drug has an important impact on research to find better treatments for this devastating cancer."

More information: CBS News Article

Copyright © 2021 HealthDay. All rights reserved.

Citation: Patients in bind as brain cancer drug price rises to $1,000 per pill (2021, June 21) retrieved 25 June 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Immunosuppression drug could reduce chemotherapy resistance


Feedback to editors